Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 26,701 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $621.02, for a total transaction of $16,581,855.02. Following the sale, the chief executive officer owned 360,191 shares of the company’s stock, valued at approximately $223,685,814.82. This represents a 6.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Medpace Stock Down 4.2%
Shares of Medpace stock traded down $26.10 on Thursday, hitting $598.08. The stock had a trading volume of 232,765 shares, compared to its average volume of 330,847. The business’s 50 day moving average is $600.14 and its two-hundred day moving average is $519.59. The stock has a market cap of $16.69 billion, a price-to-earnings ratio of 35.06, a price-to-earnings-growth ratio of 2.78 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the firm posted $3.10 EPS. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on MEDP
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Medpace during the 2nd quarter worth $1,323,047,000. State Street Corp raised its position in Medpace by 4.2% in the second quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after purchasing an additional 28,666 shares during the last quarter. Wasatch Advisors LP raised its position in Medpace by 19.4% in the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after purchasing an additional 125,625 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Medpace by 19.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock valued at $210,637,000 after purchasing an additional 60,883 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.
About Medpace
Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.
Featured Stories
- Five stocks we like better than Medpace
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
